Peripheral blood stem cells differ from bone marrow stem cells in cell cycle status, repopulating potential, and sensitivity toward hyperthermic purging in mice mobilized with cyclophosphamide and granulocyte colony-stimulating factor.

Peripheral blood stem cells (PBSCs) are increasingly used in autologous stem cell transplantations. We investigated the mobilizing effect of a combined cyclophosphamide (CTX) and granulocyte colony-stimulating factor (G-CSF) treatment on progenitor cells (STRA) and primitive stem cells (LTRA) in normal and splenectomized CBA/H mice. This combined treatment not only resulted in mobilization but also in expansion of hematopoietic stem cell subsets. The latter phenomenon was somewhat suppressed in splenectomized animals, but in these mice an enhanced mobilization of STRA and LTRA cells into the peripheral blood was observed. Furthermore, we studied the engraftment potential of mobilized PBSCs. Mice transplanted with PBSCs engrafted significantly better compared to mice transplanted with bone marrow stem cells from control and mobilized mice. The repopulation curve was characterized by a less-deep nadir indicating that the differences occur during the initial phase after transplantation. Contamination of autologous PBSC transplants with malignant cells is noticed frequently and is the basis for urging the use of purging modalities. Here we used hyperthermia and found that the mobilized progenitor cells in peripheral blood are more resistant to hyperthermia than those in the bone marrow (i.e., a survival of 11 +/- 5% after 90 min at 43 degrees C for peripheral blood progenitors, compared to 0.5 +/- 0.4% in bone marrow of mobilized animals and 1.6 +/- 0.5% in normal animals, respectively). Hyperthermic purging does not eliminate the superior repopulating features of a PBSC graft, as is demonstrated by an increased median survival time of lethally irradiated mice transplanted with purged PBSCs. In conclusion, our data demonstrate that CTX + G-CSF-mobilized PBSCs have an enhanced engraftment potential concomitantly with a decreased cycling activity and hence a decreased hyperthermic sensitivity. These findings support the use of these mobilized PBSCs for autologous stem cell transplantation and strengthen the basis for using hyperthermia as a purging modality.

[1]  E. Vellenga,et al.  Autologous peripheral blood stem cell transplantation in patients with relapsed lymphoma results in accelerated haematopoietic reconstitution, improved quality of life and cost reduction compared with bone marrow transplantation: the Hovon 22 study , 2001, British journal of haematology.

[2]  H. Kampinga,et al.  Purging of acute myeloid leukaemia cells from stem cell grafts by hyperthermia: enhancement of the therapeutic index by the tetrapeptide AcSDKP and the alkyl-lysophospholipid ET-18-OCH3 , 2000 .

[3]  N. Schmitz,et al.  Blood stem cells compared with bone marrow as a source of hematopoietic cells for allogeneic transplantation. IBMTR Histocompatibility and Stem Cell Sources Working Committee and the European Group for Blood and Marrow Transplantation (EBMT). , 2000, Blood.

[4]  F. Gherlinzoni,et al.  Use of peripheral blood stem cells for autologous transplantation in acute myeloid leukemia patients allows faster engraftment and equivalent disease-free survival compared with bone marrow cells , 1999, Bone Marrow Transplantation.

[5]  A. Gratwohl,et al.  Blood and marrow transplantation activity in Europe 1997 , 1999, Bone Marrow Transplantation.

[6]  A. Hagenbeek,et al.  Peripheral blood stem cell transplantation as an alternative to autologous marrow transplantation in the treatment of acute myeloid leukemia? , 1999, Bone Marrow Transplantation.

[7]  W. Bensinger,et al.  Peripheral blood stem cell mobilization for high-dose chemotherapy. , 1999, Journal of hematotherapy.

[8]  R. Alon,et al.  Dependence of human stem cell engraftment and repopulation of NOD/SCID mice on CXCR4. , 1999, Science.

[9]  R. Moog,et al.  Technical aspects and performance in collecting peripheral blood progenitor cells , 1998, Annals of Hematology.

[10]  A. Gratwohl,et al.  Blood and marrow transplantation activity in Europe 1996 , 1998, Bone Marrow Transplantation.

[11]  A. Pennings,et al.  The low cycling status of mobilized peripheral blood CD34+ cells is not restricted to the more primitive subfraction , 1998, Leukemia.

[12]  R. Willemze,et al.  The early phase of engraftment after murine blood cell transplantation is mediated by hematopoietic stem cells. , 1998, Proceedings of the National Academy of Sciences of the United States of America.

[13]  P. Wierenga,et al.  Reduction of heat‐induced haemotoxicity in a hyperthermic purging protocol of murine acute myeloid leukaemic stem cells by AcSDKP , 1997, British journal of haematology.

[14]  S. Nilsson,et al.  Synchronized cell-cycle induction of engrafting long-term repopulating stem cells. , 1997, Blood.

[15]  G. Schuurhuis,et al.  Hypersensitivity of bcr-abl-positive progenitors to hyperthermia in patients with chronic myeloid leukemia , 1997, Leukemia.

[16]  J. Briones,et al.  Rapid engraftment without significant graft-versus-host disease after allogeneic transplantation of CD34+ selected cells from peripheral blood. , 1997, Blood.

[17]  L. To,et al.  The biology and clinical uses of blood stem cells. , 1997, Blood.

[18]  I. Weissman,et al.  Cyclophosphamide/granulocyte colony-stimulating factor induces hematopoietic stem cells to proliferate prior to mobilization. , 1997, Proceedings of the National Academy of Sciences of the United States of America.

[19]  M. R. Ricciardi,et al.  Cycling status of CD34+ cells mobilized into peripheral blood of healthy donors by recombinant human granulocyte colony-stimulating factor. , 1997, Blood.

[20]  O. Eden,et al.  The treatment of acute leukaemia , 1997, The Lancet.

[21]  A. Tsukamoto,et al.  The unexpected G0/G1 cell cycle status of mobilized hematopoietic stem cells from peripheral blood. , 1997, Blood.

[22]  B. Löwenberg,et al.  Autologous stem-cell transplantation and purging. , 1996, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[23]  S. Ikehara,et al.  Characterization of peripheral blood stem cells in mice. , 1996, Blood.

[24]  Hiromitsu Nakauchi,et al.  Long-Term Lymphohematopoietic Reconstitution by a Single CD34-Low/Negative Hematopoietic Stem Cell , 1996, Science.

[25]  R. Donahue,et al.  Peripheral blood CD34+ cells differ from bone marrow CD34+ cells in Thy-1 expression and cell cycle status in nonhuman primates mobilized or not mobilized with granulocyte colony-stimulating factor and/or stem cell factor. , 1996, Blood.

[26]  P. Wierenga,et al.  Goralatide (AcSDKP) selectively protects murine hematopoietic progenitors and stem cells against hyperthermic damage. , 1996, Experimental hematology.

[27]  A. Roberts,et al.  Noncycling state of peripheral blood progenitor cells mobilized by granulocyte colony-stimulating factor and other cytokines. , 1995, Blood.

[28]  Moolten Dn.  Peripheral blood stem cell transplant : future directions , 1995 .

[29]  D. Huhn,et al.  Hematopoietic rescue after high-dose chemotherapy using autologous peripheral-blood progenitor cells or bone marrow: a randomized comparison. , 1995, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[30]  J. Down,et al.  Studies on the hyperthermic sensitivity of the murine hematopoietic stem cell compartment. II. Heat effect on donor stem cells with long-term repopulating ability. , 1995, Experimental Hematology.

[31]  F. Mandelli,et al.  Autologous or allogeneic bone marrow transplantation compared with intensive chemotherapy in acute myelogenous leukemia. European Organization for Research and Treatment of Cancer (EORTC) and the Gruppo Italiano Malattie Ematologiche Maligne dell'Adulto (GIMEMA) Leukemia Cooperative Groups. , 1995, The New England journal of medicine.

[32]  J. Craig,et al.  Molecular detection of tumor contamination in peripheral blood stem cell harvests. , 1994, Experimental hematology.

[33]  J. Ihle,et al.  Direct demonstration that autologous bone marrow transplantation for solid tumors can return a multiplicity of tumorigenic cells , 1994 .

[34]  L. Kanz,et al.  Mobilization of tumor cells and hematopoietic progenitor cells into peripheral blood of patients with solid tumors [see comments] , 1994 .

[35]  R. Stuart.  Autologous bone marrow transplantation for leukemia. , 1993, Seminars in oncology.

[36]  W. Janssen.  Peripheral blood and bone marrow hematopoietic stem cells: are they the same? , 1993, Seminars in oncology.

[37]  A. Freedman,et al.  Developments in purging in autotransplantation. , 1993, Hematology/oncology clinics of North America.

[38]  P. Wierenga,et al.  Studies on the hyperthermic sensitivity of the murine hematopoietic stem cell compartment. I. Heat effects on clonogenic stem cells and progenitors. , 1993, Experimental hematology.

[39]  P. Mauch,et al.  Mobilization of hematopoietic stem and progenitor cell subpopulations from the marrow to the blood of mice following cyclophosphamide and/or granulocyte colony-stimulating factor. , 1993, Blood.

[40]  W. Anderson,et al.  Gene-marking to trace origin of relapse after autologous bone-marrow transplantation , 1993, The Lancet.

[41]  R. Herrmann,et al.  Prompt haemopoietic reconstitution following hyperthermia purged autologous marrow and peripheral blood stem cell transplantation in acute myeloid leukaemia. , 1992, Bone marrow transplantation.

[42]  J. Ihle,et al.  An approach for the analysis of relapse and marrow reconstitution after autologous marrow transplantation using retrovirus-mediated gene transfer. , 1992, Blood.

[43]  M. Baert,et al.  Use of limiting-dilution type long-term marrow cultures in frequency analysis of marrow-repopulating and spleen colony-forming hematopoietic stem cells in the mouse. , 1991, Blood.

[44]  K. Kishi,et al.  Hematopoietic recovery in a patient with acute lymphoblastic leukemia after an autologous marrow graft purged by combined hyperthermia and interferon in vitro. , 1991, Bone marrow transplantation.

[45]  J. Wagner,et al.  Separation of pluripotent haematopoietic stem cells from spleen colony-forming cells , 1990, Nature.

[46]  Trickett Ae.  Tumour cell purging for autologous bone marrow transplantation. , 1990 .

[47]  Richard J. Jones,et al.  Two Phases of Engraftment Established by Serial Bone Marrow Transplantation in Mice , 1989 .

[48]  J. Bueren,et al.  Differential sensitivity to hyperthermia of mouse normal haemopoietic stem cells related to proliferation activity and organ source. , 1987, International journal of hyperthermia : the official journal of European Society for Hyperthermic Oncology, North American Hyperthermia Group.

[49]  K. Kishi,et al.  Application of hyperthermia to the treatment of human acute leukemia: purging human leukemic progenitor cells by heat. , 1986, Blood.

[50]  P. Wierenga,et al.  Enhanced selectivity of hyperthermic purging of human progenitor cells using Goralatide, an inhibitor of cell cycle progression , 1998, Bone Marrow Transplantation.

[51]  E. Shpall,et al.  Peripheral blood stem cells for autografting. , 1997, Annual review of medicine.

[52]  G. Kvalheim.  Purging of autografts: methods and clinical significance. , 1996, Annals of medicine.

[53]  L. Kanz,et al.  Purging of peripheral blood progenitor cells. , 1996, Annals of oncology : official journal of the European Society for Medical Oncology.

[54]  A. Gee.  Purging of peripheral blood stem cell grafts , 1995, Stem cells.

[55]  H. Ramshaw,et al.  Engraftment of bone marrow cells into normal unprepared hosts: effects of 5-fluorouracil and cell cycle status. , 1995, Blood.

[56]  T. Ahmed,et al.  Blood progenitor cells: collection techniques and applications. , 1994, Cancer investigation.